Abbott (NYSE: ABT) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing troublesome dyskinesia. "Off" time refers to the periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease. The results from the study will be presented as part of the Emerging Science program (formerly known as Late-Breaking) at the American Academy of Neurology's 64th Annual Meeting in New Orleans on April 25.
This study was conducted to determine the efficacy, safety and tolerability of continuous LCIG infusion in patients with advanced Parkinson's disease compared to standard levodopa-carbidopa IR tablets. LCIG contains the same active medication as levodopa-carbidopa IR tablets but in gel form and is administered directly into the small intestine via a procedurally-implanted tube connected to a portable pump. At baseline, patients enrolled in the study had Parkinson's disease for an average of 10.9 years and experienced an average of 6.6 hours of "off" time a day.
The primary efficacy endpoint was change from baseline in daily "off" time (16 waking hours) at 12 weeks.
- Mean "off" time at 12 weeks decreased by 4.0 hours per day with LCIG, an average of 1.91 fewer hours of "off" time compared to levodopa-carbidopa IR tablets.
The secondary efficacy endpoint was change from baseline in daily "on" time without troublesome dyskinesias. "On" time refers to periods of good motor symptom control.
- Mean "on" time improved by 4.1 hours with LCIG, an average of 1.86 more hours compared to levodopa-carbidopa IR tablets.
Treatment-emergent adverse events (AE) occurred in 35 patients on LCIG (95 percent) and in 34 patients on levodopa-carbidopa IR tablets (100 percent) and were similar between the two treatment groups. The most common adverse events were complication of device insertion (51 percent), abdominal pain (42 percent), procedural pain (32 percent), nausea (25 percent), constipation (21 percent), orthostatic hypotension (18 percent), post-operative wound infection (17 percent), and incision site erythema (16 percent). Treatment-related serious adverse events (SAE) were reported in five patients (14 percent) in the LCIG arm and in seven patients (21 percent) in the levodopa-carbidopa IR tablets arm. All patients that experienced an SAE recovered. Premature discontinuation because of AEs was low (4.2 percent), and similar between treatment groups.
"These results demonstrate that continuous delivery of levodopa-carbidopa intestinal gel produces statistically meaningful improvements in advanced PD patients by decreasing 'off' time and increasing 'on' time without troublesome dyskinetic symptoms," said Dr. C.W. Olanow, M.D., Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine in New York City. "These benefits in a patient group that cannot be satisfactorily controlled with standard levodopa, represent an important step forward in our efforts to treat advanced PD patients."